| 摘要 |
<p>PURPOSE: Inclusion complexes of aryl-heterocyclic salts are provided to be soluble in hydrogenous cyclodextrine solution and to be administered by a small injection volume in case of administering non-orally as a hydrogenous solution to a patient. CONSTITUTION: Compositions of matter comprising a pharmaceutically acceptable salt of an aryl-heterocyclic compound, such as ziprasidone, in a cyclodextrine. Preferred cyclodextrine are SBECD and HPBCD. The composition can comprise a dry mixture, a dry inclusion complex or an aqueous solution. The salt/cyclodextrine inclusion complex preferably provides an amount of ziprasidone of at least 2.5 mgA/ml when the complex is dissolved in water at 40 % w/v. A variety of ziprasidone salts are preferred, including the mesylate, esylate, besylate, tartrate, napsylate, and tosylate.</p> |
